The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination

Br J Dermatol. 2023 Oct 25;189(5):635-637. doi: 10.1093/bjd/ljad242.

Authors

Rebecca Favaro^{1

2}, Alessandra Formai^{1

2}, Giulia Pavia^{1

2}, Luigi Gargiulo^{1

2}, Jessica Avagliano², Mario Valenti^{1

2}, Paola Facheris², Beatrice Salsano¹, Roberta V Latorre^{1

3}, Francesco Bellinato⁴, Paolo Gisondi⁴, Alessandra Narcisi², Antonio Costanzo^{1

2}

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
² Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
³ Department of Medicine, Division of General Pathology, University of Verona, Verona, Italy.
⁴ Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.

PMID: 37463513
DOI: 10.1093/bjd/ljad242

No abstract available

MeSH terms

Antibodies, Viral
Biological Therapy
COVID-19* / prevention & control
Humans
Immunity
Psoriasis* / drug therapy
SARS-CoV-2
Vaccination

Substances

Antibodies, Viral

Grants and funding

Fondazione Cariplo